• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base





    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University







  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base





    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+



      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University


Archive for January, 2010

UPF invests £250,000 in Ai2

UK technology investment specialists, MTI Partners, has announced the investment of £250,000 from the UPF (the UMIP Premier Fund), in University of Manchester spin-out company, Ai2 Limited

Ai2 is developing an innovative peptide coating technology which is able to render medical devices and implants antibacterial, thus potentially reducing the frequency of infection.

The new investment will enable the company to progress the technology platform and seek alliances and partnerships in specific applications, including contact lenses and wound dressings.

Dr. David Holbrook, Director of MTI Partners, said: “We have been watching Ai2 develop and have been impressed with its substantial technical and commercial progress for such a young organisation.”

David continues: “We have been particularly impressed with the way the company has focussed the technology on a small number of key applications, such as contact lenses, all of which represent significant unmet need markets. We look forward to helping Ai2 grow into a successful business.”

Dr. Curtis Dobson, founder and director of Ai2, said: “We are delighted to announce the successful closure of this current round. This funding will allow us to build on our successes to date and implement and validate our technology in the hands of partners. Clinical infection is a serious problem, and with this investment we can play our part in delivering a new and lasting solution.”

Chairman of Ai2, Kevin D’Silva, said: “The arrival of the UPF Fund as a substantial shareholder, and the presence of MTI Partners on the Ai2 board, will make a substantial contribution to the direction and management of the Company during 2010 and beyond. We are currently negotiating some key license applications for our peptide technology, and the target is to commence commercialisation successfully, and as soon as possible.”

The Ai2 investment comes hot on the heels of the announcement that the NWDA has awarded a MTI Partners/YFM partnership a £9 million fund management mandate to be invested in North West SMEs.

www.a-i-2.com

CONTACT US